Manuscripts
Showing 1530 manuscripts.
Early Viral Suppression Improves Neurocognitive Outcomes in HIV-Infected Children
Citation
CS Crowell, Y Huo, K Tassiopoulos, KM Malee, R Yogev, R Hazra, RM Rutstein, SL Nichols, RA Smith, PL Williams, J Oleske, WJ Muller, PACTG 219C Study Team, PHACS. Early Viral Suppression Improves Neurocognitive Outcomes in HIV-Infected Children. AIDS. 2015. 29: 295-304. PMID: 25686678Year
2015
Journal
AIDS
Cost-effectiveness of first-line antiretroviral therapy for
HIV-infected African children less than three years of age
Citation
AL Ciaranello, K Doherty, M Penazzato, JC Lindsey, L Harrison, K Kelly, RP Walensky, S Essajee, E Losina, L Muhe, K Wools-Kaloustian, S Ayaya, MC Weinstein, P Palumbo, KA Freedberg. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than three years of age. AIDS. 2015. 29: 1247-1259. PMID: 25870982Year
2015
Journal
AIDS
Study
P1060
Psychiatric condition symptoms and antiretroviral non-adherence in US youth with perinatal HIV infection: A longitudinal study
Citation
Deborah Kacanek, Konstantia Angelidou, Paige L. Williams, Miriam Chernoff, Kenneth D. Gadow, Sharon Nachman for IMPAACT P1055 Study Team. Psychiatric condition symptoms and antiretroviral non-adherence in US youth with perinatal HIV infection: A longitudinal study. AIDS. 2015. 29: 1227-1237. PMID: 26035322Year
2015
Journal
AIDS
Study
P1055
Effect of Cytomegalovirus Co-infection on Normalization of Selected T-cell Subsets in Children with Perinatally Acquired HIV Infection Treated with Combination Antiretroviral Therapy
Citation
Suad Kapetanovic, Lisa Aaron, Grace Montepiedra, Patricia Anthony, Kasalyn Thuvamontolrat, Savita Pahwa, Sandra Burchett, Adriana Weinberg, Andrea Kovacs for the Pediatric AIDS Clinical Trials Group. Effect of Cytomegalovirus Co-infection on Normalization of Selected T-cell Subsets in Children with Perinatally Acquired HIV Infection Treated with Combination Antiretroviral Therapy. PLoS One. 2015. 10: e0120474. PMID: 25794163Year
2015
Journal
PLoS One
Characterization of functional antibody and memory B-cell responses to pH1N1 monovalent vaccine in HIV-infected children and youth
Citation
DJ Curtis, P Muresan, S Nachman, T Fenton, KM Richardson, T Dominguez, PM Flynn, SA Spector, CK Cunningham, A Bloom, A Weinberg. Characterization of functional antibody and memory B-cell responses to pH1N1 monovalent vaccine in HIV-infected children and youth. PLoS One. 2015. 3: e0118567. PMID: 25785995Year
2015
Journal
PLoS One
Study
P1088
Determinants of Vaccine Immunogenicity in HIV-Infected Pregnant Women: Analysis of B and T Cell Responses to Pandemic H1N1 Monovalent Vaccine.
Citation
Weinberg A, Muresan P, Richardson KM, Fenton T, Dominguez T, Bloom A, Watts DH, Abzug MJ, Nachman SA, Levin MJ, P1086 team. Determinants of Vaccine Immunogenicity in HIV-Infected Pregnant Women: Analysis of B and T Cell Responses to Pandemic H1N1 Monovalent Vaccine.. PLoS One. 2015. 10: e0122431. PMID: 25874544Year
2015
Journal
PLoS One
Study
P1086
Autophagy Induction by Histone Deacetylase Inhibitors Inhibits HIV Type 1
Citation
Grant R. Campbell, Rachel S. Bruckman, Stephen A. Spector. Autophagy Induction by Histone Deacetylase Inhibitors Inhibits HIV Type 1. Journal of Biological Chemistry. 2015. 290: 5028-5040. PMID: 25540204Year
2015
Journal
Journal of Biological Chemistry
Infant HIV Type 1 gp120 vaccination Elicits Robust and Durable Anti-V1V2 Immunoglobulin G responses and only Rare Envelope-Specific Immunoglobulin A Responses
Citation
Genevieve Fouda, Coleen Cunningham, E McFarland, B Borkowsky, P Muresan, J Pollara, L Y Song, B Liebl, K Whitaker, X Shen, N Vandergrift, RG Overman, N Yates, A Moody, C Fry, J Kim, N Michael, P Pitisuttithum, J Kaewkungwal, S Nitayaphan, S Rerks-Ngarm, H-X Liao,, B Haynes, D Montefiori, G Ferrari, G Tomaras, S Permar. Infant HIV Type 1 gp120 vaccination Elicits Robust and Durable Anti-V1V2 Immunoglobulin G responses and only Rare Envelope-Specific Immunoglobulin A Responses. Journal of Infectious Diseases. 2015. 211: 508-517. PMID: 25170104Year
2015
Journal
Journal of Infectious Diseases
Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age
Citation
S Nachman, C Alvero, EP Acosta, H Teppler, B Homony, B Graham, T Fenton, X Xu, ML Rizk, SA Spector, LM Frenkel, C Worrell, E Handelsman, A Wiznia. Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age. Journal of Pediatric Infectious Disease Society. 2015. 4: e76-83. PMID: 26582887Year
2015
Journal
Journal of Pediatric Infectious Disease Society
Study
P1066
Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.
Citation
RM Rutsein, P Samson, T Fenton, CV Fletcher, JJ Kiser, Mofenson LM, E Smith, B Graham, M Mathew, G Aldrovani, PACTG 1020A Study Team. Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.. Pediatric Infectious Disease Journal. 2015. 34: 162-167. PMID: 25232777Year
2015
Journal
Pediatric Infectious Disease Journal
Study
P1020A